Therapeutic area Cancer
Background info
Intellectual property

What the technology does

Polymerase with enhanced ability to process bisulphite-treated DNA and hydrophobic base analogues.


Compared to the standard enzyme of choice (Taq), polymerase 5D4 has enhanced DNA synthesis efficiency on bisulphite-treated DNA and enhanced bypass of dhU6S adducts in bisulphite-treated non-desulphonated DNA. It also has improved sensitivity in PCR amplification of bisulphite-treated DNA or uracil-containing DNA templates in general.

Main application field

Polymerase 5D4 has utility in bi-sulphite sequencing and in processing of uracil-containing DNA templates. It was originally selected for its ability to process hydrophobic base analogues, so would have wider application in this field


R&D tool


Technology ready for evaluation and licensing

Intellectual Property

Granted patents include EP2145956 and US9096835.


Non-exclusive licence

Key Contact

  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities